Maxigen Biotech Inc. (TPE:1783)
Taiwan · Delayed Price · Currency is TWD 39.80
-0.05 (-0.13%)
Jul 30, 2026, 1:30 PM CST
Maxigen Biotech Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,574 | 3,838 | 4,365 | 4,304 | 4,036 | 3,996 | |
Market Cap Growth | -10.35% | -12.06% | 1.40% | 6.65% | 0.99% | 151.22% |
Enterprise Value | 2,724 | 3,107 | 3,821 | 3,884 | 3,324 | 3,534 |
Last Close Price | 39.85 | 42.80 | 48.03 | 46.47 | 43.20 | 42.77 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.28 | 14.47 | 22.95 | 25.96 | 28.95 | 45.59 |
Forward PE | - | 10.53 | 10.53 | 10.53 | 10.53 | 10.53 |
PS Ratio | 4.33 | 4.73 | 6.41 | 6.92 | 6.68 | 7.81 |
PB Ratio | 2.20 | 2.50 | 3.17 | 3.16 | 3.12 | 3.50 |
P/TBV Ratio | 2.20 | 2.50 | 3.17 | 3.16 | 3.12 | 3.51 |
P/FCF Ratio | 16.95 | 18.42 | 16.38 | 28.94 | 15.89 | 38.67 |
P/OCF Ratio | 12.12 | 13.23 | 14.64 | 25.14 | 15.04 | 33.98 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.30 | 3.83 | 5.61 | 6.24 | 5.50 | 6.90 |
EV/EBITDA Ratio | 9.03 | 10.60 | 18.48 | 21.94 | 21.21 | 29.51 |
EV/EBIT Ratio | 10.19 | 11.90 | 21.24 | 25.92 | 25.84 | 39.28 |
EV/FCF Ratio | 12.92 | 14.91 | 14.34 | 26.11 | 13.08 | 34.20 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.06 | 0.07 | - | - | - | 0.01 |
Debt / EBITDA Ratio | 0.33 | 0.34 | - | - | - | 0.08 |
Debt / FCF Ratio | 0.47 | 0.48 | - | - | - | 0.09 |
Net Debt / Equity Ratio | -0.52 | -0.50 | -0.46 | -0.32 | -0.62 | -0.45 |
Net Debt / EBITDA Ratio | -2.82 | -2.65 | -3.09 | -2.43 | -5.10 | -4.32 |
Net Debt / FCF Ratio | -4.03 | -3.72 | -2.40 | -2.90 | -3.15 | -5.01 |
Asset Turnover | 0.45 | 0.47 | 0.44 | 0.42 | 0.45 | 0.46 |
Inventory Turnover | 3.05 | 2.83 | 2.45 | 2.46 | 2.95 | 2.98 |
Quick Ratio | 3.02 | 2.89 | 3.61 | 4.02 | 5.94 | 5.53 |
Current Ratio | 3.32 | 3.21 | 4.03 | 4.72 | 6.56 | 6.75 |
Return on Equity (ROE) | 17.46% | 18.22% | 13.90% | 12.48% | 11.44% | 8.76% |
Return on Assets (ROA) | 9.07% | 9.39% | 7.31% | 6.37% | 5.93% | 5.06% |
Return on Invested Capital (ROIC) | 30.03% | 30.34% | 18.21% | 18.05% | 19.31% | 12.57% |
Return on Capital Employed (ROCE) | 16.40% | 16.90% | 13.10% | 11.00% | 9.90% | 7.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.58% | 6.91% | 4.36% | 3.85% | 3.45% | 2.19% |
FCF Yield | 5.90% | 5.43% | 6.11% | 3.46% | 6.30% | 2.59% |
Dividend Yield | 4.99% | 4.67% | 1.73% | 2.15% | 1.10% | - |
Payout Ratio | 27.46% | 28.05% | 46.78% | 25.54% | - | 64.18% |
Buyback Yield / Dilution | -0.34% | -0.77% | -0.27% | -0.07% | -5.78% | -4.81% |
Total Shareholder Return | 4.65% | 3.91% | 1.46% | 2.08% | -4.68% | -4.81% |